4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) is a clinical-stage biotechnology company developing genetic medicines using customized adeno-associated virus vectors discovered through its Therapeutic Vector Evolution platform. Its pipeline targets retinal and lung diseases, with 4D-150, a gene therapy candidate for… From the company’s description.
Over the twelve months to Jun 30, 2026, 4D Molecular Therapeutics, Inc. reported revenue of $92.01M, up 278712.1% from a year earlier, and a net loss of $179.18M. Its operating margin was −214.2%, and operations used $156.07M in cash. In fiscal 2025, it reported revenue of $85.21M, up 230194.6% from fiscal 2024, and a net loss of $140.11M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What 4D Molecular Therapeutics, Inc. does
In the company’s own words
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) is a clinical-stage biotechnology company developing genetic medicines using customized adeno-associated virus vectors discovered through its Therapeutic Vector Evolution platform. Its pipeline targets retinal and lung diseases, with 4D-150, a gene therapy candidate for wet age-related macular degeneration and diabetic macular edema, in Phase 3 development for wet AMD; other programs include 4D-175 for geographic atrophy, 4D-710 for cystic fibrosis, and 4D-725 for alpha-1 antitrypsin deficiency. The company’s vectors are designed for tissue-specific delivery, including intravitreal injection for retinal diseases and aerosol administration for lung conditions. It develops and manufactures candidates for clinical trials in-house, supplements capacity through contract manufacturers, and expects to rely on external manufacturing for potential commercial supply. Founded in 2013, the company has developed vector libraries containing approximately one billion synthetic capsid sequences. Its single reported business is the discovery and development of genetic medicines; it reports no commercial product revenue. The company employs its platform across discovery, preclinical research, and clinical programs. Its website is https://4dmoleculartherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- EMERYVILLE, CA
- Fiscal year end
- December
- CIK
- 1650648
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns 4D Molecular Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · 4D Molecular Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do 4D Molecular Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of 4D Molecular Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in 4D Molecular Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”